Medicare Part D drugs starting with G
66 drugs start with G; 31 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Gemtesa in 2024: $945 million, what plans and patients paid at the pharmacy before rebates.
Which drugs start with G?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Gabapentin | 100% | Tier 2 | $548 million |
| Gabarone (gabapentin) | 2.4% | Tier 5 | no 2024 match |
| Galafold (migalastat) | 3% | Tier 5 | $46 million |
| Galantamine | 98% | Tier 4 | no 2024 match |
| Galantamine hydrobromide | 98% | Tier 4 | $22 million |
| Galbriela (ethinyl estradiol / norethindrone) | 43.9% | Tier 2 | no 2024 match |
| Gallifrey (norethindrone acetate) | 97.5% | Tier 2 | $28 thousand |
| Gammagard (immunoglobulin g, human) | 34.8% | Tier 5 | $581 million |
| Gammagard ERC (immunoglobulin g, human) | 23.9% | Tier 5 | no 2024 match |
| Gammaked (immunoglobulin g, human) | 34.6% | Tier 5 | $270 million |
| Gammaplex (immunoglobulin g, human) | 23.8% | Tier 5 | $296 million |
| Gamunex (immunoglobulin g, human) | 94.9% | Tier 5 | $521 million |
| Gardasil 9 (HPV vaccine) | 100% | Tier 1 | $3 million |
| Gatifloxacin | 82.7% | Tier 3 | $1 million |
| Gattex (teduglutide) | 47.6% | Tier 5 | $358 million |
| GaviLyte-C (polyethylene glycol and 4 more ingredients) | 99.7% | Tier 2 | $7 million |
| Gavilyte-G (polyethylene glycol and 4 more ingredients) | 94.7% | Tier 2 | $11 million |
| GaviLyte-N | 84.8% | Tier 2 | $265 thousand |
| Gavreto (pralsetinib) | 100% | Tier 5 | $15 million |
| Gefitinib | 100% | Tier 5 | $2 million |
| Gemfibrozil | 100% | Tier 1 | $14 million |
| Gemmily (ethinyl estradiol / norethindrone acetate) | 7.8% | Tier 2 | $9 thousand |
| Gemtesa (vibegron) | 80.6% | Tier 3 | $945 million |
| Generlac (lactulose) | 99.3% | Tier 2 | $37 thousand |
| Gengraf (cyclosporine, modified) | 80.9% | Tier 4 | $762 thousand |
| Genotropin (somatropin) | 51.9% | Tier 4 | $27 million |
| Gentamicin | 100% | Tier 2 | $13 million |
| Genvoya | 100% | Tier 5 | $552 million |
| Geodon (ziprasidone) | under 0.1% | Tier 1 | $5 million |
| Gilenya (fingolimod) | 0.5% | Tier 5 | $54 million |
| Gilotrif (afatinib) | 100% | Tier 5 | $61 million |
| Gimoti (metoclopramide) | under 0.1% | Tier 2 | $5 million |
| Glassia (alpha 1-proteinase inhibitor, human) | 2.2% | Tier 5 | $64 million |
| Glatiramer acetate | 97% | Tier 5 | $79 million |
| Glatopa (glatiramer acetate) | 96.2% | Tier 5 | $75 million |
| Gleevec (imatinib) | under 0.1% | Tier 1 | $63 million |
| Gleostine (lomustine) | 70.2% | Tier 4 | $3 million |
| Glimepiride | 100% | Tier 1 | $41 million |
| Glimepiride / pioglitazone | 47.7% | Tier 1 | $1 million |
| Glipizide | 100% | Tier 1 | $91 million |
Show the other 26 drugs
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Glipizide / metformin hydrochloride | 99.8% | Tier 1 | $12 million |
| Gloperba (colchicine) | 0.1% | Tier 4 | $33 thousand |
| Glucagon (rdna) | 44.7% | Tier 3 | no 2024 match |
| Glucose | 99.7% | Tier 2 | no 2024 match |
| Glucose / potassium chloride | 91.7% | Tier 4 | no 2024 match |
| Glucose / potassium chloride / sodium chloride | 95.1% | Tier 4 | no 2024 match |
| Glucose / sodium chloride | 100% | Tier 2 | no 2024 match |
| Glucotrol (glipizide) | under 0.1% | Tier 1 | $52 thousand |
| Glutamine | 96.5% | Tier 5 | $1 million |
| Glyburide | 23.5% | Tier 1 | $3 million |
| Glyburide / metformin hydrochloride | 20.8% | Tier 1 | $1 million |
| Glycerol phenylbutyrate | 3.6% | Tier 5 | no 2024 match |
| Glycopyrrolate | 100% | Tier 2 | $10 million |
| Glyxambi (empagliflozin / linagliptin) | 88.2% | Tier 3 | $141 million |
| Gocovri (amantadine) | 2.2% | Tier 5 | $100 million |
| Golytely (polyethylene glycol and 4 more ingredients) | 0.2% | Tier 1 | $205 thousand |
| Gomekli (mirdametinib) | 100% | Tier 5 | no 2024 match |
| Gralise (gabapentin) | 0.2% | Tier 4 | $13 million |
| Gramicidin / neomycin / polymyxin b | 99% | Tier 3 | no 2024 match |
| Granisetron | 92.8% | Tier 4 | $1 million |
| Granix (tbo-filgrastim) | 12.1% | Tier 5 | $4 million |
| Grastek (timothy grass pollen extract) | 3.7% | Tier 3 | $362 thousand |
| Griseofulvin | 100% | Tier 4 | $2 million |
| Guanfacine | 95.6% | Tier 2 | $9 million |
| Gvoke (glucagon) | 52.9% | Tier 3 | $964 thousand |
| Gynazole-1 (butoconazole nitrate) | 0.2% | Tier 4 | no 2024 match |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans